About Sonnet BioTherapeutics Holdings, Inc. (SONN)
The SEC lists Sonnet BioTherapeutics Holdings, Inc. under CIK 0001106838, in pharmaceutical preparations. It is grouped with Health Care companies on this site.
Footnote F1 (price, shares): On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub")… Full note on SEC EDGAR
Footnote F2 (price, shares): (Continued from footnote 1) Includes (i) 8,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 1,374 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the… Full note on SEC EDGAR
Footnote F3 (price, shares): On June 30, 2025, the Reporting Person was issued warrants to purchase up to 86,505 shares of Company Common Stock as partial consideration for a convertible note (the "Convertible Note") issued by the Company in favor of the Reporting Person in the principal amount of $200,000… Full note on SEC EDGAR
Footnote F4 (price, shares): (Continued from footnote 3) In connection with the cashless exercise, the Company withheld shares to pay the exercise price, based on a fair market value of $4.764 per share.
Footnote F5 (price): On July 14, 2025, the Reporting Person was issued warrants to purchase up to 320,000 shares of Company Common Stock upon the conversion in full of the Convertible Note. The warrants cannot be exercised to the extent that, after giving effect to such exercise, the Reporting… Full note on SEC EDGAR
Footnote F6 (price): On July 14, the Reporting Person was issued 200 shares of Series 5 Preferred Stock, initially convertible at a conversion price of $1.25 per share upon the conversion in full of the Convertible Note. The Series 5 Preferred Stock cannot be converted to the extent that, after… Full note on SEC EDGAR
Footnote F7 (shares): All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Footnote F8 (shares): Represents securities previously acquired in transactions exempt under Rule 16b-3.
Footnote F1 (price, shares): On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub")… Full note on SEC EDGAR
Footnote F2 (price, shares): (Continued from footnote 1) Includes (i) 6,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 446 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the… Full note on SEC EDGAR
Footnote F3 (shares): All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Footnote F1 (price, shares): . On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger… Full note on SEC EDGAR
Footnote F2 (price, shares): (Continued from footnote 1) Includes (i) 8,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 1,643 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the… Full note on SEC EDGAR
Footnote F3 (shares): All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Footnote F1 (price, shares): On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub")… Full note on SEC EDGAR
Footnote F2 (price, shares): (Continued from footnote 1) Includes (i) 20,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 2,356 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the… Full note on SEC EDGAR
Footnote F3 (shares): All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Footnote F1 (price, shares): On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub")… Full note on SEC EDGAR
Footnote F2 (price, shares): (Continued from footnote 1) Includes (i) 10,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 547 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the… Full note on SEC EDGAR
Footnote F3 (shares): All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Footnote F1 (price, shares): On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub")… Full note on SEC EDGAR
Footnote F2 (price, shares): (Continued from footnote 1) Includes (i) 4,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 394 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the… Full note on SEC EDGAR
Footnote F3 (shares): All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Footnote F1 (price, shares): On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub")… Full note on SEC EDGAR
Footnote F2 (price, shares): (Continued from footnote 1) Includes (i) 12,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 2,116 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the… Full note on SEC EDGAR
Footnote F3 (shares): All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Footnote F1 (price, shares): On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub")… Full note on SEC EDGAR
Footnote F2 (price, shares): (Continued from footnote 1) Includes (i) 10,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 375 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the… Full note on SEC EDGAR
Footnote F3 (shares): All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Footnote F1 (price, shares): On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub")… Full note on SEC EDGAR
Footnote F2 (price, shares): (Continued from footnote 1) Includes (i) 4,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 537 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the… Full note on SEC EDGAR
Footnote F3 (shares): All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Sonnet BioTherapeutics Holdings, Inc. (SONN) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-12-04. The full record for SONN runs to 29 Form 4 filings, the earliest from 2024-12-05. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SONN stock?
No insider purchases of SONN were filed in the last 90 days.
How many insiders are selling SONN stock?
No insider sales of SONN were filed in the last 90 days.
Where can I see SONN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SONN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Richard T. Kenney - OfficerDerivative9,374 sh
Nailesh Bhatt - Director
Albert D. Dyrness - Director
